<p>Immutep Limited（納斯達克股票代碼：IMMP - 獲取免費報告）的股票在週四的交易中跌破了其 50 日移動平均線。該股票的 50 日移動平均線為 2.18 美元，最低交易價為 1.80 美元。Immutep 的股票最後交易價為 1.84 美元，成交量為 70,057 股。</p>
<h2>Immutep 股票上漲 0.5%</h2>
<ul>
<li>Immutep Ltd 股票為何近期飆升？</li>
</ul>
<p>該公司的 50 日移動平均價格為 2.18 美元，200 日移動平均價格為 2.35 美元。公司的流動比率為 18.25，速動比率為 18.25，債務股本比率為 0.01。</p>
<h2>機構投資者對 Immutep 的看法</h2>
<p>機構投資者和對沖基金最近增加或減少了對該公司的持股。XTX Topco Ltd 在第二季度購買了 Immutep 的新股份，價值約 26,000 美元。BNP Paribas Financial Markets 在第一季度將其在 Immutep 的持股增加了 15.4%。BNP Paribas Financial Markets 目前擁有 35,300 股該生物技術公司的股票，價值 82,000 美元，此前在該期間又購買了 4,700 股。XY Capital Ltd 在第二季度購買了 Immutep 的新股份，價值約 105,000 美元。Virtu Financial LLC 在第一季度將其在 Immutep 的持股增加了 269.4%。Virtu Financial LLC 目前擁有 45,062 股該生物技術公司的股票，價值 105,000 美元，此前在上個季度又購買了 32,864 股。最後，Oracle Investment Management Inc.在第一季度將其在 Immutep 的持股增加了 9.4%。Oracle Investment Management Inc.目前擁有 564,879 股該生物技術公司的股票，價值 1,316,000 美元，此前在該期間又購買了 48,449 股。2.32% 的股票由機構投資者持有。</p>
<h2>Immutep 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Immutep Limited 是一家臨牀階段的生物技術公司，專注於開發用於癌症和自身免疫疾病的新型 LAG-3 免疫療法。該公司致力於推進與淋巴細胞激活基因-3（LAG-3）相關的治療，LAG-3 是一種在調節免疫系統中發揮重要作用的細胞表面分子。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票而非 Immutep</li>
<li>如何使用 MarketBeat Excel 股息計算器</li>
<li>吉利德股票飆升：是什麼推動了這一勢頭？</li>
<li>萬億美元市值的意義超越數字</li>
<li>突破警報：高通剛剛按下了反彈按鈕</li>
<li>如何投資保險公司：指南</li>
<li>Mercado Libre 股票降價：現在是購買的時機嗎？</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<p>→ 緊急：這次選舉是操控的（來自 Porter &amp; Company）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDA1Nw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDA1Nw"/></p>
<h2>你現在應該投資 1,000 美元在 Immutep 嗎？</h2>
<p>在考慮 Immutep 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Immutep 並不在名單上。</p>
<p>雖然 Immutep 目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

IMMP

<p>Immutep（納斯達克代碼：IMMP）股價跌破其 50 日移動均線 0.18 美元，最低交易價為 0.80 美元，最終收於 0.84 美元，成交量為 70,057 股。該公司的流動比率為 18.25，債務股本比率為 0.01。機構投資者最近調整了他們的持股，像法國巴黎銀行和 Virtu Financial 等公司顯著增加了持股。Immutep 是一家臨牀階段的生物技術公司，專注於開發用於癌症和自身免疫疾病的 LAG-3 免疫療法</p>

<p>Shares of Immutep Limited (NASDAQ:IMMP - Get Free Report) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.18 and traded as low as $1.80. Immutep shares last traded at $1.84, with a volume of 70,057 shares traded.</p>
<div class="lb-trans"><p>Immutep Limited（納斯達克股票代碼：IMMP - 獲取免費報告）的股票在週四的交易中跌破了其 50 日移動平均線。該股票的 50 日移動平均線為 2.18 美元，最低交易價為 1.80 美元。Immutep 的股票最後交易價為 1.84 美元，成交量為 70,057 股。</p>
</div><h2>Immutep Stock Up 0.5 %</h2>
<div class="lb-trans"><h2>Immutep 股票上漲 0.5%</h2>
</div><ul>
<li>Why Did Immutep Ltd Stock Soar Recently?</li>
</ul>
<div class="lb-trans"><ul>
<li>Immutep Ltd 股票為何近期飆升？</li>
</ul>
</div><p>The company's 50-day moving average price is $2.18 and its 200-day moving average price is $2.35. The company has a current ratio of 18.25, a quick ratio of 18.25 and a debt-to-equity ratio of 0.01.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均價格為 2.18 美元，200 日移動平均價格為 2.35 美元。公司的流動比率為 18.25，速動比率為 18.25，債務股本比率為 0.01。</p>
</div><h2>Institutional Investors Weigh In On Immutep</h2>
<div class="lb-trans"><h2>機構投資者對 Immutep 的看法</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in shares of Immutep in the 2nd quarter valued at about $26,000. BNP Paribas Financial Markets grew its holdings in Immutep by 15.4% during the first quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company's stock worth $82,000 after purchasing an additional 4,700 shares during the period. XY Capital Ltd bought a new position in Immutep during the second quarter worth about $105,000. Virtu Financial LLC increased its position in Immutep by 269.4% during the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company's stock worth $105,000 after buying an additional 32,864 shares during the last quarter. Finally, Oracle Investment Management Inc. raised its stake in Immutep by 9.4% in the first quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company's stock valued at $1,316,000 after buying an additional 48,449 shares during the period. 2.32% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近增加或減少了對該公司的持股。XTX Topco Ltd 在第二季度購買了 Immutep 的新股份，價值約 26,000 美元。BNP Paribas Financial Markets 在第一季度將其在 Immutep 的持股增加了 15.4%。BNP Paribas Financial Markets 目前擁有 35,300 股該生物技術公司的股票，價值 82,000 美元，此前在該期間又購買了 4,700 股。XY Capital Ltd 在第二季度購買了 Immutep 的新股份，價值約 105,000 美元。Virtu Financial LLC 在第一季度將其在 Immutep 的持股增加了 269.4%。Virtu Financial LLC 目前擁有 45,062 股該生物技術公司的股票，價值 105,000 美元，此前在上個季度又購買了 32,864 股。最後，Oracle Investment Management Inc.在第一季度將其在 Immutep 的持股增加了 9.4%。Oracle Investment Management Inc.目前擁有 564,879 股該生物技術公司的股票，價值 1,316,000 美元，此前在該期間又購買了 48,449 股。2.32% 的股票由機構投資者持有。</p>
</div><h2>Immutep Company Profile</h2>
<div class="lb-trans"><h2>Immutep 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.</p>
<div class="lb-trans"><p>Immutep Limited 是一家臨牀階段的生物技術公司，專注於開發用於癌症和自身免疫疾病的新型 LAG-3 免疫療法。該公司致力於推進與淋巴細胞激活基因-3（LAG-3）相關的治療，LAG-3 是一種在調節免疫系統中發揮重要作用的細胞表面分子。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Immutep</li>
<li>How to Use the MarketBeat Excel Dividend Calculator</li>
<li>Gilead’s Stock Surge: What’s Fueling the Momentum?</li>
<li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li>
<li>Breakout Alert: Qualcomm Just Hit The Rally Button</li>
<li>How to Invest in Insurance Companies: A Guide</li>
<li>Mercado Libre Shares Go on Sale: Is Now the Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票而非 Immutep</li>
<li>如何使用 MarketBeat Excel 股息計算器</li>
<li>吉利德股票飆升：是什麼推動了這一勢頭？</li>
<li>萬億美元市值的意義超越數字</li>
<li>突破警報：高通剛剛按下了反彈按鈕</li>
<li>如何投資保險公司：指南</li>
<li>Mercado Libre 股票降價：現在是購買的時機嗎？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><p>→ Urgent: This election is rigged (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 緊急：這次選舉是操控的（來自 Porter &amp; Company）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDA1Nw" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10057&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Immutep right now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Immutep 嗎？</h2>
</div><p>Before you consider Immutep, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Immutep 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immutep wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Immutep 並不在名單上。</p>
</div><p>While Immutep currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Immutep 目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Immutep（NASDAQ:IMMP）股價跌破五十日移動平均線 - 事情是這樣的